Article
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/September-2017/0707s4cvr.gif)
A randomized phase III trial of BIBW 2992 versus chemotherapy as first-line treatment for stage IIIB/IV adenocarcinoma of the lung harboring an epidermal growth factor receptor-activating mutation
- Author:
- Lecia V. Sequist, MD, MPH
- Chih-Hsin James Yang, MD
Publish date: July 1, 2010